The NCAA's Recent Q&A Document: Clues on What NIL Enforcement Will Look Like Post-House — Highway to NIL Podcast
The Labor Law Insider: NLRB Does a U-Turn on Make-Whole Settlement Remedies, Part II
The Labor Law Insider: NLRB Does a U-Turn on Make-Whole Settlement Remedies, Part I
Compliance into the Weeds: Boeing, a NPA and the End of Monitors
House Final Settlement Hearing: Key Insights and Future Implications for NIL — Highway to NIL Podcast
What is the House v. NCAA settlement and how does this ruling affect college sports?
Episode 302 -- Matt Stankiewicz on DOJ's Massive Criminal Settlement with Cryptocurrency Exchange Binance and its CEO Changpeng Zhao
State AG Pulse | AGs to Forever Chemicals Cos: We Want More Money and We Want It Now
Settlement Agreement Update Between the DOJ and Meta - The Consumer Finance Podcast
California Employment News: The Erosion of Confidentiality Clauses in Settlement Agreements
Mediating Complex Insurance Coverage Disputes Series Part 4 - How to Seal the Deal
#WorkforceWednesday: NLRB Outlook, NY Whistleblower Protections Take Effect, DOJ to Focus on Cyber-Fraud - Employment Law This Week®
What Will Happen at My Mediation?
VIDEO: Update on Third Party Workers’ Compensation Settlements in Pennsylvania
Episode 119 -- The Ericsson FCPA Settlement
Episode 118 -- Update on OFAC Enforcement and Lessons Learned
Episode 117 -- FCPA Update: Samsung FCPA Settlement; Braskem Former CEO Indicted; Transport CEO Convicted after Trial
II-35- The New Sexual Harassment Training/Policy Requirements in New York State and New York City
[WEBINAR] Labor & Employment Law: What Changed in 2017
II-26 – Superbowl Concerns, Tax Reform/MeToo, Restrictive Covenant Crimes, and Expanded Religious Discrimination Theories
Illumina, Inc., a publicly-traded biotechnology company, agreed to a $9.8 million settlement with the U.S. Department of Justice (DOJ) in response to alleged violations of the False Claims Act (FCA). DOJ alleged that Illumina...more
Ensuring compliance with the False Claims Act has never been more important for healthcare providers. By March 2020, we saw healthcare professionals standing at the forefront of one of the greatest health crises in a...more
In 2019, U.S. Department of Justice (DOJ) enforcement activity targeting drug and device manufacturers jumped sharply over the prior year, reflecting an increased focus on fraud and abuse in the life sciences sector. More...more
A LOOK BACK... A LOOK AHEAD - While the uncertainty associated with legislative efforts to repeal the Patient Protection and Affordable Care Act (PPACA) dominated most of the headlines for the healthcare industry last year,...more